

DEVELOPMENT OF DELTA AMINO LEVULINIC ACID

AUXOTROPHIC OF *VIBRIO CHOLERA*E O1

EL TOR OGAWA

NUR HASLINDAWATY BTE ABD RASHID

UNIVERSITI SAINS MALAYSIA

2005

**DEVELOPMENT OF DELTA AMINO LEVULINIC ACID
AUXOTROPHIC OF *VIBRIO CHOLERAE* O1
EL TOR OGAWA**

BY

NUR HASLINDAWATY BTE ABD RASHID

Thesis submitted in fulfillment of the requirements
for the degree of Master of Science

April 2005

DEDICATIONS

I would like to dedicate this thesis to my parents, Mr. Abd Rashid Bin Yusoff and Mrs. Semek Binti Che Stapha. Special dedication to my caring husband, Wan Hashim Bin Wan Mamat and not forget my lovely son, Wan Amirul Hannan. Thank you for your support and encouragement during my research study.

ACKNOWLEDGEMENTS

For their invaluable contribution in the successful completion of the thesis, I would like to express my deepest gratitude to the following:

First and foremost to my supervisor Dr. Manickam Ravichandran whom I cannot thank enough. For his continuous assistance and advice for the duration of this study and for his great patience and effort in developing my knowledge, experience and understanding, especially in the field of research and laboratory management.

To my co-supervisor Prof Dr. Zainul Fadziruddin Zainuddin for his advice and encouragement, especially towards my laboratory experiments. Special thank also to Dr. P. Lalitha for her guidance and encouragement during the research progress.

To my very energetic colleague Mr. Atif Ali for his great assistance both technically and theoretically. Also a special thank you to Mrs. Chan Yean Yean, Mr. Halkimi and Ms. Katriena for their help.

Thank you to USM for giving Pasca Scholarship during my study. Special dedication to Malaysian Government for support this study under long term grant number 304/PPSP/6110257.

LIST OF CONTENTS

Content	Page no.
TITLE	
DEDICATIONS	ii
ACKNOWLEDGEMENTS	iii
LIST OF CONTENTS	iv
LIST OF TABLES	x
LIST OF FIGURES	xi
LIST OF ABBREVIATIONS	xiv
ABSTRACT	xvii
ABSTRAK	xviii
CHAPTER 1 INTRODUCTION	1
1.1 Historical Background	1
1.2 <i>Vibrio cholerae</i>	3
1.3 <i>Vibrio cholerae</i> O1	6
1.4 Structure of cholera toxin	8
1.5 Cholera toxin	10
1.6 Epidemiology	11
1.7 Pathogenesis and Pathophysiology	14
1.8 Clinical features	16
1.9 Diagnosis	17
1. 10 Treatment	18
1. 11 <i>hemM</i> and <i>hemA</i> of <i>Vibrio cholerae</i>	20

1.12	Vaccines	24
1.12.1	Parenteral Vaccines	25
1.12.2	Oral Vaccines	26
1.12.2.1	Whole Cell B–Subunit	27
1.12.2.2	Recombinant live Attenuated Cholera Vaccine	30
1.13	Future Cholera Vaccines	35
1.14	Kanamycin Resistant Gene	36
1.15	Green Fluorescent Protein	37
1.16	The Goal of the Research	40
1.16.1	Objectives of the study	40
1.17	Research Design	41
CHAPTER 2	MATERIALS AND METHODS	44
2.1	MATERIALS	44
2.1.1	Chemicals/Reagents/Antibodies/Culture Media	44
2.1.2	Kits	45
2.1.3	Consumables	46
2.1.4	Culture Media	47
2.1.4.1	Luria Bertani (LB) Agar	47
2.1.4.2	Luria Bertani (LB) Broth	47
2.1.4.3	Modified LB Agar without NaCl and With 10% Sucrose	47
2.1.4.4	Modified LB Broth without NaCl and With 10% Sucrose	48
2.1.4.5	TCBS Agar	48
2.1.4.6	Addition of Antibiotics/Supplements to the Agar	49
2.1.5	General Buffers, Stock Solutions, Antibiotics	49
2.1.5.1	δ -Aminolevulinic Acid 40 mg/ml	49
2.1.5.2	Ampicillin 100 mg/ml	49
2.1.5.3	Calcium Chloride 100 mM	50
2.1.5.4	Ethanol 95%	50
2.1.5.5	Ethanol 70%	50
2.1.5.6	EDTA 0.5 M	50
2.1.5.7	Ethidium bromide 10 mg/ml	51
2.1.5.8	Gel Loading Dye 6X	51
2.1.5.9	Sucrose 30%	52
2.1.5.10	Hydrochloric Acid 1 N	52
2.1.5.11	IPTG 20%	52
2.1.5.12	Kanamycin 50 mg/ml	53
2.1.5.13	Magnesium Chloride 1 M	53

2.1.5.14 Magnesium Chloride 100 mM	53
2.1.5.15 Normal Saline	54
2.1.5.16 Polymyxin B 0.75 mg/ml (450 units)	54
2.1.5.17 Sodium Hydroxide 10 M	54
2.1.5.18 Skimmed Milk 10%	55
2.1.5.19 Tris Acetic Acid EDTA (TAE) 50X	55
2.1.5.20 Tris Borate EDTA (TBE) 10X	55
2.1.5.21 Tris hydrochloride 10 mM (pH 7.4)	56
2.1.5.22 X-gal (20 mg/ml)	56
2.1.6 Bacterial Species and Strains	56
2.1.6.1 <i>E.coli</i> BW 20767- λ pir	56
2.1.6.2 <i>E.coli</i> DH5 α - λ pir	57
2.1.6.3 <i>E.coli</i> TOP10	57
2.1.6.4 <i>V. cholerae</i> O1 El Tor Ogawa strain	57
2.1.6.5 VCUSM3	57
2.1.6.6 VCUSM4	57
2.1.7 Plasmids	57
2.1.7.1 pARO 180	57
2.1.7.2 pARO- <i>hemA</i> /M	58
2.1.7.3 pARO- <i>hemA</i> /M-kan	58
2.1.7.4 pARO- <i>hemA</i> /M-gfp	58
2.1.7.5 pTOPO 2.1	58
2.1.7.6 pTOPO- <i>hemA</i> /M	58
2.1.7.7 pWM91	58
2.1.7.8 pWM91- <i>hemA</i> /M-kan	58
2.1.7.9 pWM91- <i>hemA</i> /M-gfp	58
2.1.7.10 pWM91- <i>hemA</i> */M	59
2.1.8 General Instruments	59
2.2 METHODS	62
2.2.1 Bacterial Strains and Culture Conditions	62
2.2.2 Medium Term Storage of Bacterial Strains as Glycerol Stock	62
2.2.2.1 Recovery of Bacteria from Glycerol Stock	63
2.2.3 Long Term Storage of Bacterial Strains as Lyophilized Stock	63
2.2.3.1 Recovery of Bacteria from Lyophilized Stock	64
2.2.4 Confirmation of <i>V. cholerae</i> O1 El Tor Ogawa by Serotyping	64
2.2.5 Primer Designing	65
2.2.5.1 Primers for <i>hemA</i> /M Gene	65
2.2.5.2 Internal Primers for <i>hemA</i> /M	65
2.2.5.3 Primers for Kanamycin Gene	66
2.2.5.4 Primers for GFP Gene	66
2.2.6 Preparation for Bacterial Lysate and Patching	67

2.2.7	PCR Amplification	67
2.2.8	Agarose Gel Electrophoresis	68
2.2.8.1	Preparation of Agarose Gel	68
2.2.8.2	Loading of the Sample	69
2.2.8.3	Running the Gel and Visualization of the DNA	69
2.2.9	Purification of PCR Product	69
2.2.9.1	Purification of PCR Product/DNA Fragment from Agarose Gel	70
2.2.10	Cloning of PCR Amplified Product onto pTOPO Vector	70
2.2.11	Preparation of Competent <i>E. coli</i> Cells	71
2.2.11.1	Preparation of Competent Cells by CaCl ₂ Method	71
2.2.12	Transformation of Ligated Vector into Competent Cells	72
2.2.13	Selection of Positive Clone by Alpha Complementation	72
2.2.14	Plasmid Extraction	73
2.2.14.1	Preparation of Bacterial Culture for Plasmid Extraction	73
2.2.14.2	Plasmid Extraction using Qiagen Kit	74
2.2.15	Quantitation of DNA	74
2.2.15.1	Quantitation of DNA using UV Spectroscopy	75
2.2.15.2	Quantitation of DNA on Agarose Gel	75
2.2.16	DNA Restriction	76
2.2.16.1	Restriction Conditions for <i>EcoRI</i>	76
2.2.16.2	Restriction Conditions for <i>BstXI</i>	76
2.2.16.3	Restriction Conditions for <i>SmaI</i>	77
2.2.17	Dephosphorylation Using Shrimp Alkaline Phosphatase	77
2.2.18	Ligation	78
2.2.19	T4 DNA Polymerase Treatment	78
CHAPTER 3 CLONING and of <i>hemA/M</i> GENE OF <i>VIBRIO CHOLERAE</i>		80
3.1	Cloning Strategy	80
3.2	Cloning of <i>hemA/M</i>	80
3.2.1	PCR amplification of <i>hemA/M</i>	81
3.2.2	PCR cloning in pTOPO2.1 Vector	83
3.2.3	Cloning onto a Shuttle pARO180	89

3.3	Amplification of Kanamycin Cassette	92
3.3.1	Insertional Mutation of <i>hemA</i> Gene with Kanamycin Cassette	92
3.4	Positive Selection Suicide Vector pWM91	98
3.4.1	Subcloning of Mutated <i>hemA</i> -kan onto Suicide Vector pWM91	100
3.5	Amplification of Green Fluorescent Protein (GFP)	105
3.5.1	Mutation of <i>hemA</i> Gene with GFP	105
3.5.2	Subcloning of Mutated <i>hemA</i> with GFP onto Suicide Vector pWM91	114
CHAPTER 4 RECOMBINATION OF MUTATED <i>hemA</i> IN <i>VIBRIO CHOLERAE</i>		121
4.1	Recombination in Bacteria	121
4.2	Conjugation	121
4.2.1	Conjugative Transfer of pWM91 Carrying Mutated <i>hemA</i> -kan in <i>V. cholerae</i> O1 El Tor	124
4.2.1.1	First Recombination	125
4.2.1.2	Result for First Recombination of pWM91- <i>hemA</i> -kan in <i>V. cholerae</i> O1 El Tor	126
4.2.1.3	Selection for Loss of the Suicide Vector from Transconjugants	130
4.2.2	Conjugative Transferred of pWM91- Δ <i>hemA</i> */M into VCUSM3	139
4.2.2.1	First Recombination Event for pWM91- Δ <i>hemA</i> */M into VCUSM3	140
4.2.2.2	Result for First Recombination of pWM91- Δ <i>hemA</i> */M into VCUSM3	141
4.2.2.3	Selection for Loss of the Suicide Vector from pWM91- Δ <i>hemA</i> */M	145
4.3	Characterization of the <i>V. cholerae hemA</i> mutant	154
4.4	Discussion	161
CHAPTER 5 DISCUSSION		166
CHAPTER 6 CONCLUSION		178
REFERENCES		180

APPENDIX I	194
APPENDIX II	198
APPENDIX III	201

LIST OF TABLES

Table		Page no.
1.1	Differential characteristics of selected members of the <i>Vibrionaceae</i> and <i>Enterobacteriaceae</i> .	4
1.2	Characteristic features of <i>hemM</i> and <i>hemA</i> gene	22
1.3	Similarity percentage of <i>V. cholerae hemM</i> and <i>hemA</i> gene with other organisms	23
4.1	Results of the first recombination	128
4.2	Results for enumeration control for first recombination	128
4.3	Growth pattern of transconjugants after sucrose selection in different media	132
4.4	Growth characterization for selected colonies after second recombination	133
4.5	Final confirmation of the <i>hemA</i> mutants using different media	135
4.6	Results of the first recombination	142
4.7	Results for enumeration control for first recombination	142
4.8	Growth pattern of transconjugants after sucrose selection in different media	147
4.9	Growth characterization for selected colonies after second recombination	148
4.10	Final concentration of the markerless <i>hemA</i> mutants using different media	149

LIST OF FIGURES

Figure	Page no.
1.1 Map of <i>ctxA</i> and <i>ctxB</i> gene and its corresponding ORF coordinate	9
1.2 Map showing the distribution of cholera worldwide	13
1.3 Experimental overview for VCUSM3 construction	42
1.4 Experimental overview for VCUSM4 construction	43
3.1 A 2180 bp <i>hemA/M</i> PCR amplified from <i>Vibrio cholerae</i> biotype El Tor Serotype Ogawa by using VHR and VHF primers	82
3.2 PCR amplification of 2180 bp <i>hemA/M</i> from <i>V. cholerae</i> O1 El Tor serotype Ogawa and subsequent cloning onto a PCR cloning vector pTOPO2.1	85
3.3 PCR screening of the pTOPO2.1- <i>hemA/M</i> with M13R and VHR primers	86
3.4 PCR screening of the <i>hemA/M</i> insert in pTOPO2.1- <i>hemA/M</i> with VHR and VHF primers	87
3.5 A 2180 bp <i>hemA/M</i> was excised from pTOPO2.1- <i>hemA/M</i> with <i>EcoRI</i>	88
3.6 Restriction analysis of pARO180- <i>hemA/M</i> with <i>EcoRI</i> enzyme	91
3.7 Kanamycin cassette PCR amplified from pTOPO2.1 using KR1 and KS1 primers	94
3.8 Restricted <i>hemAM</i> gene 7.64 kb in pARO180- <i>hemAM</i> with <i>BstXI</i>	95
3.9 pARO180- <i>hemAM</i> -kan colonies PCR screening with 18R3 and VHA-AS4 primers	96
3.10 Subcloning of <i>hemAM</i> gene from pTOPO onto a shuttle vector pARO180 and subsequent insertion of kan ^R into the <i>hemA</i> gene by blunt end ligation	97
3.11 Suicide vector pWM91 plasmid map	99
3.12 A 3.34 kb Δ <i>hemA</i> -kan restricted from pARO180- <i>hemAM</i> -kan with <i>EcoRI</i>	101
3.13 Restriction digestion of the pWM91 with <i>SmaI</i> enzyme	102
3.14 Subcloning of <i>hemAM</i> mutated with kanR onto a suicidal vector pWM91	103

3.15	PCR screening of pWM91- <i>hemA</i> -kan with 18R3 and VHA-AS4	104
3.16	Agarose gel electrophoresis of PCR amplicon of GFP	108
3.17	PCR screening of pTOPO2.1-GFP clones with GFP-F and GFP-R primers	109
3.18	Subcloning of <i>hemA/M</i> gene from pTOPO onto a shuttle vector pARO180 and subsequent insertion of GFP into the <i>hemA</i> gene by blunt end ligation	110
3.19	PCR screening of mutated <i>hemA/M</i> -gfp in pAROGFP1-5 with 18R3 and VHA-AS4 primers	111
3.20	Restriction analysis pARO180- <i>hemA/M</i> -gfp with <i>Sma</i> I	112
3.21	Restriction analysis of pARO180- <i>hemAM</i> -gfp with <i>Eco</i> RI	113
3.22	PCR screening with VHA-AS4 and 18R4 primers for confirmation of the presence of Δ <i>hemA</i> -gfp into pWM91- <i>hemAM</i> -gfp	116
3.23	Subcloning of 3.2 kb <i>hemAM</i> mutated with GFP onto a suicidal vector pWM91 at <i>Sma</i> I site	117
3.24	A 992 bp fragment of GFP excised out from pWM91- <i>hemAM</i> -gfp restricted with <i>Sma</i> I	118
3.25	Deletion of GFP from pWM91- <i>hemA/M</i> -gfp and formation of pWM91- Δ <i>hemA</i> */M with frame shift mutation in <i>hemA</i>	119
3.26	PCR screening for confirmation of pWM91- <i>hemA</i> */M with VHA-AS4 and 18R3	120
4.1	PCR screening of transconjugants after first recombination with VHA-AS4 and 18R4 primers	129
4.2	Schematic representation of homologous recombination and formation of <i>hemA</i> mutant	136
4.3	PCR confirmation of Δ <i>hemA</i> -kan (VCUSM3) with VHA-AS4 and 18R3 primers	137
4.4	PCR amplification of Δ <i>hemA</i> -kan from VCUSM3 strains with VHA-AS4 and 18R3 primers for sequencing	138
4.5	PCR screening of transconjugants with VHA-AS4 and 18R4 primers and confirmation of merodiploids	144
4.6	PCR screening of markerless frame shift <i>hemA</i> mutants with VHA-AS4 and 18R4 primers	152
4.7	PCR amplification of VCUSM4 (Δ <i>hemA</i> */M) with VHA-AS4 and 18R3	153

primers for DNA sequencing

- 4.8** Growth profile of wild type, VCUSM3 and VCUSM4 strains on LB plain plate and LB plate supplemented with ALA 155
- 4.9** Growth profile of wild type, VCUSM3 and VCUSM4 strains on TCBS plate and TCBS plate supplemented with ALA 156
- 4.10** Growth characterization of wild type, VCUSM3 and VCUSM4 strain on LB plate ALA and kanamycin and LB plate polymyxin B 158
- 4.11** Growth characterization of wild type, VCUSM3 and VCUSM4 strain on blood agar plate 159

LIST OF ABBREVIATIONS

2X	2 times
AA	Amino acid
AMP	Ampicillin
AMPK	Ampicillin and Kanamycin
AMPKA	Ampicillin, Kanamycin and ALA
ALA	Aminolevulinic acid
bp	Base pair
CTX	Cholera toxin
CTXA	Cholera toxin A subunit
CTXB	Cholera toxin B subunit
CTXΦ	<i>ctx</i> phage
DNA	Deoxyribonucleic acid
dNTP	Deoxynucleotide triphosphate
EDTA	Ethylene diamine tetra acetic acid
GFP	Green fluorescent protein
GMO	Genetically modified organism
HCl	Hydrochloric acid
Hg	Mercury
IPTG	Isopropyl-beta-D-thiogalactopyranoside
KA	Kanamycin and ALA
Kan	Kanamycin
kb	kilo base
L	Liter
LB	Luria Bertani
MCS	Multiple cloning site
ml	milliliter
mm	millimeter
min	minute
mRNA	messenger ribonucleic acid
mw	Molecular weight
NaCl	Sodium chloride
nm	Nanometer

NS	Normal Saline
Nt	Nucleotide
°C	Degree centigrade
ORS	Oral Rehydration Solution
ORT	Oral Rehydration Therapy
P	Polymyxin B
PA	Polymyxin B and ALA
PAMPKA	Polymyxin B, Ampicillin, Kanamycin and ALA
PCR	Polymerase Chain Reaction
PK	Polymyxin Band Kanamycin
PKA	Polymyxin, Kanamycin and ALA
PL	Plain
pH	Potential hydrogen ion
RE	Restriction endonuclease
SA	10% sucrose and amino levulenic acid
TAE	Tris/acetate/EDTA (buffer)
Taq	<i>Thermus aquaticus</i>
TBE	Tris/borate/EDTA (buffer)
TCBS	Thiosulfate Citrate Bile salt Sucrose
TCBSA	Thiosulfate Citrate Bile salt Sucrose and ALA
TE	Tris/EDTA (buffer)
Tm	Melting temperature
tRNA	transfer ribonucleic acid
u	unit
UV	Ultraviolet
USA	United State of America
<i>V. cholerae</i>	<i>Vibrio cholerae</i>
VCUSM3	Δ hemA-kan <i>Vibrio cholerae</i> El Tor
VCUSM4	Δ hemA*/M <i>Vibrio cholerae</i> El Tor
v/v	volume/volume
w/v	weight/volume
WHO	World Health Organization
X-Gal	5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside
µm	Micrometer

ABSTRACT

Cholera is an important diarrheal disease in developing countries. WHO estimates that cholera caused 111,575 cases with 1,894 deaths in the year 2003 worldwide. To overcome that problem, a number of cholera vaccine candidates have been developed by mutation or deletion of various genes such as $\Delta thyA$ and Δgln . However, these auxotrophic strains were leaky and able to grow in the small intestine of experimental animal's *in-vivo*. Objective of the study was to develop an auxotrophic vaccine strains by mutating the housekeeping gene, *hemA* gene in *V. cholerae*. The *hemA* gene codes for glutamyl tRNA reductase. The *hemA* gene plays a major rate-limiting step in delta aminolevulinic acid (ALA). The *hemA* gene was PCR amplified from *V. cholerae* O1 El Tor and cloned into pARO180 vector at *EcoRI* site. To mutate the *hemA* gene, a kanamycin cassette was inserted at the *BstXI* site. $\Delta hemA$ -kan was first subcloned into conjugative suicide vector pWM91 which was then, conjugatively transferred into *V. cholerae* O1 El Tor and the mutant obtained was designated as VCUSM3. In order to remove the kanamycin cassette, the *hemA* gene was inserted with GFP gene flanking with *SmiI* site and subcloned onto pWM91. GFP gene was then excised and left a +1 frame shift mutation in *hemA* gene ($\Delta hemA^*/M$). $\Delta hemA^*/M$ was conjugatively transferred to VCUSM3 and the mutant obtained was designated as VCUSM4. ALA auxotrophy of VCUSM3 and VCUSM4 were confirmed by their growth on ALA supplemented medium. The *hemA* mutants were confirmed by PCR using *hemA* specific primers and by DNA sequencing. Thus in this study ALA auxotrophs of *V. cholerae* O1 El Tor were created by mutating the *hemA* gene.

**PEMBANGUNAN AUXOTROPIK DELTA ASID AMINO LEVULINIK
PADA *VIBRIO CHOLERAE* O1 EL TOR OGAWA**

ABSTRAK

kolera merupakan penyakit cirit-birit yang penting di negara-negara membangun. Pada tahun 2003, WHO menganggarkan sebanyak 111,575 kes kolera dengan 1,894 kematian berlaku di seluruh dunia. Untuk mengatasi masalah ini, beberapa vaksin kolera telah dicipta melalui memutasikan atau mendelesikan berbagai-bagai jenis gen seperti $\Delta thyA$ dan Δgln . Walaubagaimanapun, strain auxotropik ini didapati berupaya hidup di dalam usus kecil haiwan kajian di makmal. Oleh itu, kajian ini bertujuan untuk membangunkan vaksin auxotropik melalui mutasi gen “housekeeping” pada *V. cholerae* iaitu gen *hemA*. Gen *hemA* mengkodkan untuk enzim glutamyl tRNA reductase. Ia berperanan sebagai penentu kadar di dalam pembentukan ALA. Gen *hemA* di PCR amplifikasikan daripada *V. cholerae* O1 El Tor dan diklonkan kedalam vector pARO180 pada kedudukan *EcoRI*. Kaset kanamycin dimasukkan pada kedudukan *BstXI* untuk memutasikan gen *hemA*. $\Delta hemA$ -kan disubklonkan kedalam vector pWM91. Seterusnya, ia dipindahkan secara konjugatif kepada *V. cholerae* O1 El Tor, dan menghasilkan VCUSM3. Kaset kanamycin disingkirkan melalui pengantian dengan GFP yang mempunyai *SmiI* pada kedua-dua hujungnya dan disubklonkan ke dalam vector pWM91. “Frame shift” +1 terhasil apabila *gfp* disingkirkan. Mutan VCUSM4 dihasilkan apabila $\Delta hemA^*/M$ dipindahkan secara konjugatif kepada VCUSM3. ALA auxotropik VCUSM3 dan VCUSM4 disahkan melalui pertumbuhan pada medium agar yang dibekalkan dengan ALA. PCR menggunakan primer spesifik terhadap *hemA* dan

analisis penjujukan DNA dilakukan untuk mengesahkan mutan *hemA*. Kajian ini telah berjaya, menghasilkan *V. cholerae* O1 El Tor ALA auxotropik melalui kaedah mutasi pada gen *hemA*.

CHAPTER 1

INTRODUCTION

1.1 Historical Background

There have been seven pandemics of cholera in recorded history. Even though the etiological agents of the first four pandemics are not known since they occurred in the time before such agents could be recognized, the last three pandemics are known to be due to *Vibrio cholera* serogroup O1. The modern history of cholera began in 1817, when cholera spread out of India described as the first of seven pandemics (Pollitzer, 1959). The disease poured out of Bengal, extending far beyond its normal habitat, and attacked large populations in many countries. The first pandemic recorded from 1817 to 1823, reaching China and Japan to the East; to the West, it spread to the shores of the Mediterranean and Zanzibar on the east coast of Africa (Pollitzer, 1959; Snow, 1855). The pandemic ended when the disease completely disappeared from any region outside India. In early 1830, the second pandemic of cholera reached the British Isles, Russia, Poland, Austria, Ireland and France. Cholera was first reintroduced into China in 1840 by British troops transferred from India.

The third pandemic was stated by Pollitzer to have begun in 1852, extending to Persia and Mesopotamia and to Europe. Whereas, the fourth pandemic occurred in 1873 and the outbreak was stopped in 1875. In 1881 the fifth pandemic extensively affected South

America; it caused large epidemics in many countries and was characterized by high mortality in Argentina, Chile and Peru (Laval, 1989). During the fifth pandemic, Robert Koch successfully isolated the causative organism of cholera, referred to as “comma bacilli” (Koch, 1884), from rice water stools of patients in Egypt in 1883 and in India in 1884. The sixth pandemic began in 1899; disease persisted in Eastern Europe until 1923. According to John *et al.*, (2000), cholera has been epidemic in Southern Asia for at least 1000 years, but also spread worldwide to cause seven pandemics since 1817.

The seventh pandemic is the most extensive of the pandemics in geographic spread and in duration. The pandemic, which began in 1961 on the island of Sulawesi in Indonesia, spread to other islands, including Java, Sarawak, and Borneo and then to the Philippines, Sabah and Taiwan, thereby affecting the entire Southeast Asian archipelago by the end of 1962 (Kamal, 1974). In 1992, epidemic cholera was reported in Madras and other places in India and in Southern Bangladesh (Cholera Working Group, 1993; Ramamurthy *et al.*, 1993). Although the clinical syndrome was typical of cholera, the causative agent was a *V. cholerae* non-O1 strain, which was later serogrouped as O139 and given the synonym name “Bengal” (Shimada *et al.*, 1993). This new serogroup may represent the etiologic agent of a new eight pandemic of cholera.

The word “Cholera” has been used for over 2,500 years to describe any diarrhea and vomiting, not just that caused by bacteria. There is considerable debate over the origin of the term cholera and which ancient cultures the disease touched. According to the works of Hippocrates, it was believed that the word has been derived from the Greek word “chole” (bile) and “rein” (flow), which means, “flow of bile”. Whereas another possible derivation is from the Hebrew, meaning “bad disease” (Kaper *et al.*, 1995). Alexander Trallianus, however said that the word had come from “cholades” which

means intestine, as the evacuations were often serous and not bilious (Diman Barua and Greenough, 1992).

1.2 *Vibrio cholerae*

Members of the genus *Vibrio* are Gram negative, nonsporing, and straight or curved rods measuring about 0.5 to 0.8 μm in diameter and 1.4 to 2.1 μm in length (Kay *et al.*, 1994). Stephen (2001) described *V. cholerae* as a “comma - shaped” bacterium. Only aerobic or facultatively anaerobic rods with fermentative metabolism have been retained in this genus. Most species are oxidase positive. A biochemical test characteristic between *Vibrio cholerae* and Enterobacteriaceae was showed in Table 1.1.

The genus *Vibrio* contains more than 50 species, including three species that are frequently isolated from human clinical samples; *V. cholerae*, *V. parahaemolyticus* and *V. vulnificus*, and four other species that are isolated more rarely; *V. alginolyticus*, *V. fluvialis*, *V. hollisae* and *V. mimicus*. About one third of these species in the genus *Vibrio* are pathogenic for humans. The most pathogenic *Vibrio. spp* are motile by monotrichous or loptrichous flagella which are surrounded by the sheath in liquid media (Kenneth, 2000). On solid media they may synthesize numerous lateral flagella, which are not sheathed. *Vibrio cholerae* grow in alkaline conditions up to a maximum of pH 10 but sensitive to acidic conditions, where most are dying in the stomach, where the pH is 6 or below (Pollitzer, 1959).

Table 1.1 Differential characteristics of selected members of the *Vibrionaceae* and *Enterobacteriaceae* (Kay *et al.*, 1994).

Test	Reaction ^a						
	<i>Vibrio cholerae</i>	<i>Vibrio mimicus</i>	<i>Halophilic vibrios</i>	<i>Aeromonas hydrophila</i>	<i>Aeromonas veronii</i>	<i>Plesiomonas shigelloides</i>	<i>Enterobacteriaceae</i>
KIA	K/A	K/A	V	V	K/AG	K/A	V
TSI	A/A	K/A	V	V	A/AG	K/A	V
String	+	+	+ ^b	-	-	-	-
Oxidase	+	+	+	+	+	+	-
Gas from glucose	-	-	- ^c	+	+	-	V
Sucrose	+	-	V	V	+	-	V
Lysine	+	+	V	V	+	+	V
Arginine	-	-	V	+	-	+	V
Ornithine	+	+	V	-	+	+	V
VP	V	-	V	V	+	-	V
Growth in 0% NaCl ^d	+	+	-	+	+	+	+
Growth in 1% NaCl ^d	+	+	+	+	+	+	+

a+, positive; a-, negative; V, variable reaction; K, alkaline; A, acid; G, gas produced.

^b *V. parahaemolyticus*; *V. cincinnatiensis*, and *V. damsela* show variable reactions.

^c *V. furnissii* and *V. damsela* are variable.

^d Nutrient broth base.

Vibrios are one of the most common organisms in surface waters of the world. They occur in both marine and freshwater habitats and in association with aquatic animals (Charles *et al.*, 1994). Studies of the organism in the environment have found that *vibrio* is able to survive for extended periods in aquatic and estuarine areas. The survival of *V. cholerae* in the environment was thought to be short which less than one week is in seawater (Chavalier *et al.*, 1980). However, since *vibrios* are typically marine organisms most species require 2–3% NaCl or a seawater base for optimal growth. Most *vibrios* have relatively simple growth factor requirements and will grow in synthetic media with glucose as a sole source of carbon and energy. *Vibrios* vary in their nutritional versatility, but some species will grow on more than 150 different organic compounds as carbon and energy sources, occupying the same level of metabolic versatility as *Pseudomonas*.

Most pathogenic *vibrio* species are found as part of the autochthonous microbial community in brackish and marine environments in temperate or tropical regions throughout the world. *Vibrio cholerae* and *V. mimicus* have been isolated from fresh water lakes and rivers and from birds and herbivores in areas geographically removed from marine and coastal water (Bockemuhl *et al.*, 1986; Ogg *et al.*, 1989; Rhobes *et al.*, 1985 and 1986). The incidence and density of pathogenic *vibrio. spp* decrease significantly as water temperatures fall below 20°C. *Vibrio. spp* also can be found in the water column and surface sediment and are associated with mollusks and crustaceans. *Vibrio cholerae*, *Vibrio parahaemolyticus* and *Vibrio vulnificus* are known to be pathogens of humans. Both *Vibrio cholerae* and *Vibrio parahaemolyticus* produce diarrhea, but in ways that are entirely different. *V. parahaemolyticus* is an invasive organism affecting primarily the colon, whereas *V. cholerae* is non invasive and